Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework
Fresenius Medical Care (NYSE:FMS), the global leader in renal disease products and services, has announced the launch of a significant share buyback program. The company will initiate a first tranche of up to EUR 600 million, part of a larger EUR 1 billion total buyback program spanning two years.
The initial tranche is scheduled to complete by April 30, 2026, while the overall program will run until August 10, 2027. This initiative is a key component of FME's new capital allocation framework and FME Reignite strategy, aimed at enhancing shareholder value. The company serves approximately 300,000 dialysis patients through its network of 3,676 clinics worldwide.
Fresenius Medical Care (NYSE:FMS), leader mondiale nei prodotti e servizi per le patologie renali, ha annunciato l'avvio di un importante programma di riacquisto di azioni. L'azienda dar脿 il via a una prima tranche fino a EUR 600 milioni, parte di un pi霉 ampio programma di riacquisto complessivo di EUR 1 miliardo distribuito su due anni.
La tranche iniziale 猫 prevista in completamento entro il 30 aprile 2026, mentre l'intero programma si estender脿 fino al 10 agosto 2027. Questa iniziativa rappresenta un elemento chiave del nuovo quadro di allocazione del capitale di FME e della strategia FME Reignite, con l'obiettivo di accrescere il valore per gli azionisti. L'azienda serve circa 300.000 pazienti in dialisi attraverso la sua rete di 3.676 cliniche in tutto il mondo.
Fresenius Medical Care (NYSE:FMS), l铆der mundial en productos y servicios para enfermedades renales, ha anunciado el lanzamiento de un importante programa de recompra de acciones. La compa帽铆a iniciar谩 una primera fase de hasta 600 millones de EUR, que forma parte de un programa total de recompra de 1.000 millones de EUR con una duraci贸n de dos a帽os.
La fase inicial est谩 prevista para completarse antes del 30 de abril de 2026, mientras que el programa global se prolongar谩 hasta el 10 de agosto de 2027. Esta iniciativa es un componente clave del nuevo marco de asignaci贸n de capital de FME y de la estrategia FME Reignite, destinada a aumentar el valor para los accionistas. La compa帽铆a atiende aproximadamente a 300.000 pacientes en di谩lisis mediante su red de 3.676 cl铆nicas en todo el mundo.
Fresenius Medical Care (NYSE:FMS)電� 鞁犾灔 歆堩櫂 甏�霠� 鞝滍拡 氚� 靹滊箘鞀� 攵勳暭鞚� 旮�搿滊矊 靹犽憪旮办梾鞙茧, 雽�攴滊 鞛愳偓欤� 毵れ瀰 頂勲攴鸽灗鞚� 鞁滌瀾頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 斓滊寑 6鞏� 鞙犽(EUR 600 million) 攴滊鞚� 觳� 韸鸽灉旃�毳� 鞁れ嫓頃橂┌, 鞚措姅 2雲勳棎 瓯胳箿 齑� 10鞏� 鞙犽(EUR 1 billion) 攴滊鞚� 毵れ瀰 頂勲攴鸽灗鞚� 鞚茧秬鞛呺媹雼�.
觳� 氩堨Ц 韸鸽灉旃橂姅 2026雲� 4鞗� 30鞚�旯岇 鞕勲霅� 鞓堨爼鞚措┌, 鞝勳泊 頂勲攴鸽灗鞚� 2027雲� 8鞗� 10鞚�旯岇 歆勴枆霅╇媹雼�. 鞚� 臁办箻電� 欤检＜ 臧�旃橂ゼ 雴掛澊旮� 鞙勴暅 FME鞚� 靸堧鞖� 鞛愲掣 氚半秳 觳搓硠鞕� FME Reignite 鞝勲灥鞚� 頃奠嫭 鞖旍唽鞛呺媹雼�. 須岇偓電� 鞝� 靹戈硠 3,676臧� 韥措Μ雼� 雱ろ姼鞗岉伂毳� 韱淀暣 鞎� 300,000氇呾潣 韴劃 頇橃瀽鞐愱矊 靹滊箘鞀るゼ 鞝滉车頃橁碃 鞛堨姷雼堧嫟.
Fresenius Medical Care (NYSE:FMS), leader mondial des produits et services pour les maladies r茅nales, a annonc茅 le lancement d'un important programme de rachat d'actions. La soci茅t茅 lancera une premi猫re tranche pouvant atteindre 600 millions d'EUR, qui s'inscrit dans le cadre d'un programme total de rachat de 1 milliard d'EUR sur deux ans.
La tranche initiale doit 锚tre finalis茅e d'ici le 30 avril 2026, tandis que le programme global s'茅tendra jusqu'au 10 ao没t 2027. Cette initiative constitue un 茅l茅ment cl茅 du nouveau cadre d'allocation de capital de FME et de la strat茅gie FME Reignite, visant 脿 accro卯tre la valeur pour les actionnaires. La soci茅t茅 dessert environ 300 000 patients en dialyse via son r茅seau de 3 676 cliniques dans le monde.
Fresenius Medical Care (NYSE:FMS), der globale Marktf眉hrer f眉r Produkte und Dienstleistungen im Bereich Nierenerkrankungen, hat den Start eines bedeutenden Aktienr眉ckkaufprogramms angek眉ndigt. Das Unternehmen wird eine erste Tranche von bis zu EUR 600 Millionen durchf眉hren, die Teil eines gr枚脽eren insgesamt EUR 1 Milliarde umfassenden R眉ckkaufprogramms 眉ber zwei Jahre ist.
Die anf盲ngliche Tranche soll bis zum 30. April 2026 abgeschlossen sein, w盲hrend das Gesamtprogramm bis zum 10. August 2027 l盲uft. Diese Ma脽nahme ist ein zentraler Baustein des neuen Kapitalallokationsrahmens von FME und der FME Reignite-Strategie mit dem Ziel, den Aktion盲rswert zu steigern. Das Unternehmen betreut weltweit rund 300.000 Dialysepatienten 眉ber sein Netzwerk von 3.676 Kliniken.
- Implementation of EUR 600 million initial share buyback tranche, demonstrating strong commitment to shareholder returns
- Total buyback program of EUR 1 billion over two years shows significant capital return potential
- Program complements existing dividend policy, enhancing overall shareholder value proposition
- Strong market position as world's leading provider of renal disease products and services
- Significant cash outflow for buyback could impact available capital for business investments
- Extended program timeline until 2027 suggests gradual rather than immediate capital return
Insights
FME launches substantial 鈧�600M share buyback, signaling management confidence and enhancing shareholder returns through strategic capital deployment.
Fresenius Medical Care has announced the first 鈧�600 million tranche of its planned 鈧�1 billion share buyback program, set to complete by April 2026 as part of its new capital allocation framework. This represents a significant financial commitment from the dialysis industry leader and directly enhances shareholder value in several ways.
The buyback effectively reduces the number of outstanding shares, potentially increasing earnings per share and supporting share price performance. This substantial capital return signals strong management confidence in FME's financial position and future cash flow generation capabilities, particularly meaningful as it follows their recently announced FME Reignite strategy.
What makes this announcement particularly noteworthy is the size and structure of the program. The 鈧�600 million initial tranche represents approximately
This move demonstrates a systematic approach to capital allocation, balancing shareholder returns with the company's growth initiatives. By implementing regular share buybacks alongside a consistent dividend policy, FME is establishing a more comprehensive shareholder return framework that provides investors with greater predictability and potentially higher total returns.
- Total volume of the initial share buyback is up to
EUR 1 billion over two years - Share buyback to take place until August 10, 2027
BAD HOMBURG,
"With the share buyback program, we are rapidly implementing an important component supporting our new FME Reignite strategy. The new program relates to听initial share buybacks totaling
"The implementation of regular share buybacks in addition to a consistent dividend policy is part of our new capital allocation framework," stated Martin Fischer, CFO of Fresenius Medical Care. 听
FME will provide regular updates on the progress of the share buyback program at .
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,676 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 300,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website at .
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the
Media contact
Sven Jacobsen
T +49 171 28 79 127
[email protected]
Sabine Blessing
T +49 171 74 81 259
[email protected]听
Contact for Analysts and Investors
Ilia K眉rten听
T +49 6172 685 966
[email protected]听
听
View original content to download multimedia:
SOURCE Fresenius Medical Care Holdings, Inc.
FAQ
What is the size of Fresenius Medical Care's (FMS) new share buyback program?
When will FMS complete the first tranche of its share buyback program?
How long will the entire FMS share buyback program run?
What is the purpose of Fresenius Medical Care's share buyback program?
How many dialysis patients does Fresenius Medical Care serve globally?
